-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166

Benzinga·07/08/2026 16:56:40
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $168 to $166.